Our findings add a novel candidate into this emerging and fast-developing field, as low circulating IRX3 promoter methylation predicted a worse outcome after TAVI, and thus might aid as a biomarker for identify AS patients at higher risk and to monitor these patients more closely, even though the increased risk of mortality may not be due to cardiac factors. The gene discussed is IRX3; the disease is aortic stenosis.